EMSAM (deprenyl patch): how a promising antidepressant was underutilized [Corrigendum]
Asnis GM, Henderson MA. Neuropsychiatr Dis Treat. 2014;10:1911–1923.On page 1921 “[…] Dye and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb” should be “Dey and now Mylan Pharmaceutical took over the marketing o...
Guardado en:
Autores principales: | Asnis GM, Henderson MA |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/41acde07226d49a9b1fe02a82eac6b89 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
EMSAM (deprenyl patch): how a promising antidepressant was underutilized
por: Asnis GM, et al.
Publicado: (2014) -
Shen-Qi-Jie-Yu-Fang has antidepressant effects in a rodent model of postpartum depression by regulating the immune organs and subsets of T lymphocytes
por: Qu M, et al.
Publicado: (2015) -
Levomilnacipran for the treatment of major depressive disorder: a review
por: Asnis GA, et al.
Publicado: (2015) -
Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors
por: Laine Thomas, et al.
Publicado: (2021) -
Antidepressant therapy with milnacipran and venlafaxine
por: Lucilla Mansuy
Publicado: (2010)